The pharmacokinetics of tizanidine, a new centrally acting muscle relaxant, have been
studied in 18 normal male volunteers who received orally a single 5 mg dose, a single 20 …

Aims: Tizanidine, one of the few oral antispastic therapies approved for use in the USA, has
a narrow therapeutic index that can often make optimal patient dosing difficult. We surveyed …

The time-course of plasma concentrations of the antispasticity agent tizanidine were
measured by a specific radioimmune-assay in six adults who had severe spasticity due to …

A simple, sensitive and rapid high‐performance liquid chromatography/positive ion
electrospray tandem mass spectrometry (MS/MS) method was developed and validated for …

The pharmacokinetic and clinical properties of a modified release formulation of the α2-
adrenergic agonist tizanidine are reviewed. Therapy with conventional tizanidine tablets is …

Synopsis The central α 2 adrenoceptor agonist tizanidine is a myotonolytic agent used in the
treatment of spasticity in patients with cerebral or spinal injury. Wide interpatient variability in …

BACKGROUND:: An immediate-release, multiparticulate capsule formulation of tizanidine
has been developed to modify tizanidine pharmacokinetic characteristics in an attempt to …

Objectives: Explain the mechanism of action of tizanidine. Identify the clinical indications for
tizanidine use. Review the adverse reaction profile of tizanidine. Summarize inter …

In a double blind, placebo controlled, cross over study the correlations between single
doses (2, 4, and 8 mg), plasma concentrations, and antispastic action of tizanidine were …

Pharmacokinetics and pharmacodynamics of tizanidine. - Abstract - Europe PMC Sign in |
Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact …